LAS VEGAS: GB Sciences, Inc. (OTCQB: GBLX) has entered into a Contract Research Agreement with the Universidad de Sevilla (USE) to develop a time-released version of GB Sciences' proprietary, THC-free, myrcene-based chronic pain formulations.
GB Sciences has identified USE as having top-notch nanotechnology experts, excellent research facilities, and state-of-the art scientific equipment. The group working with GB Sciences on this important project is headed by Dr. Mercedes Fernandez Arevalo and Dr. Lucia Martin Banderas.

"Our research group has been diligently working on the development of new oral drug delivery systems. We design nanometric systems able to offer the greatest control and effectiveness of the drug taking into account physicochemical and biopharmaceutical drug properties. This is the case of our recently developed cannabinoid nanosystems. More recently, we were involved in the development of nanosystems intended to actively target specific diseases, which involves developing more complex nanosystems with highly specific surface properties," said Dr. Mercedes Fernandez Arevalo (I+DNanomed, Website:

In May of 2017, GB Sciences filed a provisional patent application for myrcene-containing complex mixtures for chronic pain relief (among other uses). GB Sciences is now collaborating with USE to develop a suitable nanotech-based delivery mechanism that would provide a steady release of active ingredients over time, which is very desirable for chronic conditions.

"Some patients who need relief from chronic pain, do not want the psychoactive effects of THC found in other cannabis-based therapies. GB Sciences' THC-free pain formulation may be just what they need," said Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences. "However, we believe that developing a time-released formulation in conjunction with USE would increase the effectiveness of our chronic pain therapy and improve patient compliance. Time-release formulas are taken less frequently and achieve more consistent pain relief over time."

"GB Sciences is proud of our affiliation with USE," said John Poss, CEO of GB Sciences, "together we will develop a line of time release formulations for medications to best meet the needs of patients all around the world."

(Posted on 17 October 2017, 1686333185 172O70O43O48)